This inventor holds 2 USPTO granted patents. Top assignees: Isis Innovation Limited, Oxxon Therapeutics Limited. Active years: 2002-2008.
Company Filing History:
Years Active: 2002-2008
Title: Aylwin Ng: Innovator in Chemokine-Binding Proteins
Introduction
Aylwin Ng is a prominent inventor based in Singapore, known for his contributions to the field of biomedicine. He has developed innovative solutions aimed at treating conditions related to inflammation through his research on chemokine-binding proteins. With a total of 2 patents, Ng's work has significant implications for therapeutic applications.
Latest Patents
Ng's latest patents include a recombinant poxvirus that utilizes a novel chemokine-binding protein designated A41L. This protein is designed for the treatment of various inflammatory conditions. The A41L protein specifically binds to chemokines in the CXC group, showcasing its potential in therapeutic interventions. Another patent focuses on a soluble vaccinia virus protein that also binds chemokines, further emphasizing the versatility and importance of the A41L protein in medical research.
Career Highlights
Throughout his career, Aylwin Ng has worked with notable companies such as Oxxon Therapeutics Limited and Isis Innovation Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Ng has collaborated with various professionals, including Geoffrey L. Smith, enhancing the depth and impact of his research endeavors.
Conclusion
Aylwin Ng's innovative work in chemokine-binding proteins positions him as a key figure in the biomedical field. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for inflammatory conditions.